证券代码：688265 证券简称：南模生物 公告编号：2025-059 上海南方模式生物科技股份有限公司 关于2025年第二次临时股东大会增加临时提案 暨股东大会补充通知的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 1. 股东大会的类型和届次： 2025年第二次临时股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | A 股 | 688265 | 南模生物 | 2025/9/18 | 二、 增加临时提案的情况说明 公司已于2025 年 8 月 30 日公告了股东大会召开通知，合计持有18.5%股份 的股东苏州海望合纵一号股权投资合伙企业（有限合伙）、上海浦东新兴产业投 资有限公司，在2025 年 9 月 11 日提出临时提案并书面提交股东大会召集人。股 东大会召集人按照《上海证券交易所科创板上市公司自律监管指引第 1 号—规范 2. 股东大会召开日期：2025 年 9 月 23 日 3. 股东大会股权登记日： 1. 提 ...

Core Viewpoint - Nanmo Biology's stock price has declined significantly, currently trading at 54.64 yuan, representing a drop of 4.09%, and is in a state of loss since its IPO [1] Company Overview - Nanmo Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an initial stock issuance of 19.49 million shares at a price of 84.62 yuan per share [1] - The stock reached its highest price of 82.00 yuan on its first trading day [1] Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 1.649 billion yuan, with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan [1] - The company planned to raise 400 million yuan for various projects, including a biological research base and the development of genetically modified animal models [1] - The total issuance costs for the IPO were 181 million yuan, with underwriting fees amounting to 158 million yuan [1]

上海南方模式生物科技股份有限公司 证券代码：688265 证券简称：南模生物 公告编号：2025-057 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 9 日（星期二）至 9 月 15 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海南 方 模 式 生 物 科 技 股 份 有 限 公 司 （ 以 下 简 称 " 公 司 " ） 邮 箱 ir@modelorg.com 提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 公司已于 2025 年 8 月 29 日发布公司《2025 年半年度报告》，为 便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财 务状况，公司计划于 2025 年 9 月 16 日（星期二）13:00-14:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半 ...

Core Viewpoint - The CXO industry is experiencing a recovery after a period of decline, driven by increased profitability among companies and a favorable capital market environment for stock prices [1][4][10]. Group 1: Industry Performance - In the first half of this year, 16 out of 28 A-share CXO companies reported a year-on-year increase in net profit, a significant rise from only 7 companies in the same period last year, indicating a recovery trend [1][3]. - Among the 28 stocks, 8 companies achieved a net profit increase of over 100%, with Chengdu Xian Dao leading at 390.72% [4]. - The total revenue for WuXi AppTec reached approximately 20.8 billion yuan, a year-on-year increase of 20.64%, with a net profit of about 8.56 billion yuan, up 101.92% [4]. Group 2: Market Dynamics - The recovery in the CXO industry is attributed to three main drivers: active pharmaceutical investment and business development transactions, a shift in global pharmaceutical research focus towards biologics and complex molecules, and technological innovations such as AI in drug development [5][11]. - The overall market for CXO services is expanding as pharmaceutical companies increasingly outsource research and development to specialized firms, which helps reduce costs and improve efficiency [5][11]. Group 3: Company-Specific Insights - Despite the overall recovery, some companies like Tigermed reported declines in both revenue and net profit, highlighting a disparity in performance within the industry [6][8]. - Tigermed's revenue fell to approximately 3.25 billion yuan, a decrease of 3.21%, with a net profit of about 383 million yuan, down 22.22% [6][7]. - Companies with diversified client bases and technological advantages are better positioned to capitalize on market recovery, while those reliant on single business lines may face longer adjustment periods [8]. Group 4: Stock Market Performance - All 28 CXO stocks have seen price increases this year, reflecting the industry's recovery [9][10]. - The stock price increases range from 10% to over 100%, with Nanjing Momo Bio leading at a 142.21% increase [10]. - The stock price performance correlates with improved company earnings, indicating a supportive fundamental backdrop for the sector [10].

Core Viewpoint - The CXO industry is experiencing a recovery after a challenging period, with a significant increase in the number of companies reporting profit growth in the first half of the year, indicating a positive trend in the sector [1][3][4]. Financial Performance - In the first half of this year, 16 out of 28 A-share CXO companies reported profit growth, representing approximately 57.14% of the sector [4]. - Notably, 8 companies achieved a doubling of net profit, with Chengdu Xian Dao leading at a 390.72% increase, followed by Nanmo Biology at 298.69% [4]. - Wu Ming Kang De reported the highest net profit among the companies, with approximately 8.56 billion yuan in net profit, a 101.92% year-on-year increase, and revenue of about 20.80 billion yuan, up 20.64% [4]. - Kang Long Hua Cheng, despite a 37% decline in net profit to approximately 701 million yuan, achieved a record high revenue of 6.44 billion yuan, a 14.93% increase [4][5]. Market Dynamics - The recovery in the CXO industry is driven by three main factors: increased activity in pharmaceutical investment and business development transactions, a shift in global pharmaceutical research focus towards biopharmaceuticals and complex molecules, and technological innovations such as AI in drug development [5][6]. - The overall market for CXO services is expanding as pharmaceutical companies increasingly outsource research and development to specialized firms, which helps reduce costs and improve efficiency [5][6]. Performance Disparities - Despite the overall recovery, some companies like Tai Ge Yi Yao and Yi Nuo Si reported declines in both revenue and net profit, indicating uneven recovery across the sector [6][8]. - Tai Ge Yi Yao's revenue fell by 3.21% to approximately 3.25 billion yuan, with a net profit decline of 22.22% to about 383 million yuan, primarily due to decreased income from clinical trial services [6][7]. Stock Market Trends - All 28 CXO stocks have seen price increases this year, reflecting the industry's recovery [9][10]. - The stock price increases range from 10% to over 100%, with Nanmo Biology achieving the highest increase of 142.21% [10]. - The positive stock performance is supported by improved financial results and a favorable global investment environment in pharmaceuticals [10][11]. Future Outlook - The CXO industry is expected to continue its growth trajectory, driven by an aging global population and increasing health demands, although only companies with core competitive advantages will thrive [11][12].

Market Overview - The Shanghai Composite Index closed at 3813.56 points, with a decline of 1.16% [1] - The total trading volume of A-shares reached 23956.82 billion yuan [1] Technical Analysis - A total of 16 A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sichuang Medical (300078) with a distance of -0.91% - Nanmo Biology (688265) with a distance of -0.80% - Shandong Weida (002026) with a distance of -0.75% [1] Individual Stock Performance - Sichuang Medical (300078) saw a decrease of 2.81% with a trading turnover rate of 3.15% [1] - Nanmo Biology (688265) decreased by 0.16% with a turnover rate of 1.39% [1] - Shandong Weida (002026) declined by 2.93% with a turnover rate of 2.90% [1] - Qingda Environmental (688501) dropped by 3.86% with a turnover rate of 1.84% [1] - Pulit (002324) fell by 2.62% with a turnover rate of 2.03% [1] - Other notable declines include: - Meili (000815) down by 4.03% - Hezhong (002383) down by 6.95% [1]

Group 1 - The medical services sector experienced a decline of 1.19% on September 2, with Nanmo Bio leading the drop [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable stock performances included Digital Human, which rose by 19.55% to a closing price of 20.30, and TaiGe Pharmaceutical, which increased by 1.78% to 66.25 [1] Group 2 - The medical services sector saw a net outflow of 2.03 billion yuan from main funds, while retail investors contributed a net inflow of 1.307 billion yuan [3] - The table of individual stock fund flows indicates varying levels of investment activity across different companies within the sector [3]

Core Points - Nanmo Bio (688265.SH) closed at 56.09 yuan, with a decline of 6.73%, resulting in a total market capitalization of 4.373 billion yuan [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an initial stock issuance of 19.49 million shares at a price of 84.62 yuan per share [1][2] - The stock reached an intraday high of 82.00 yuan on its first trading day, but is currently in a state of decline [2] Fundraising and Financials - Nanmo Bio raised a total of 1.649 billion yuan through its initial public offering (IPO), with a net amount of 1.468 billion yuan after deducting issuance costs [2] - The net fundraising amount exceeded the original plan by 1.068 billion yuan, as the company initially aimed to raise 400 million yuan for various projects [2] - The total issuance costs for the IPO amounted to 181 million yuan, with underwriting and sponsorship fees accounting for 158 million yuan [3]

Financial Performance - Company reported total revenue of 196 million yuan for the first half of 2025, a year-on-year increase of 10.69% [1] - Net profit attributable to shareholders reached 18.17 million yuan, up 298.69% year-on-year [1] - In Q2 alone, total revenue was 107 million yuan, reflecting a 14.32% increase compared to the same quarter last year [1] - Q2 net profit attributable to shareholders was 19.13 million yuan, a significant rise of 409.77% year-on-year [1] - Gross margin improved by 18.09% year-on-year, reaching 52.11% [1] - Net margin increased by 279.5% year-on-year, standing at 9.28% [1] - Total expenses (selling, administrative, and financial) amounted to 47.25 million yuan, accounting for 24.14% of revenue, a decrease of 24.05% year-on-year [1] - Earnings per share (EPS) was 0.23 yuan, up 291.67% year-on-year [1] Business Evaluation - The company's return on invested capital (ROIC) was 0.47% last year, indicating weak capital returns [2] - Historical median ROIC since listing is 3.18%, suggesting average investment returns [2] - The company has experienced three years of losses since its listing, indicating a fragile business model [2] - The net profit margin last year was 1.7%, suggesting low added value in products or services [2] Debt and Cash Flow - The company has a healthy cash asset position, indicating good debt repayment capability [2] - Operating cash flow per share was 0.05 yuan, a significant increase of 145.89% year-on-year [1] Accounts Receivable - The accounts receivable situation is concerning, with accounts receivable to profit ratio reaching 1962.96% [2]

Buyback and Reduction Plan - The company repurchased a total of 788,912 shares from February 23, 2024, to May 22, 2024, accounting for 1.0119% of the total share capital, aimed at maintaining company value and shareholder rights [1] - The company plans to reduce up to 779,635 shares, not exceeding 1% of the total share capital, through centralized bidding from September 19, 2025, to December 18, 2025 [2][3] - The repurchased shares will be sold within 12 months after the announcement of the buyback results, and if not sold within three years, the untransferred shares will be canceled [1][3] Shareholder Information - The repurchase account holds 2,346,309 shares, representing 3.01% of the total share capital, which will decrease to 1,566,674 shares, or 2.01%, after the planned reduction [4] - The company has not sold any shares from the repurchase account since its listing [2] Financial Impact - The funds recovered from the share reduction will be included in the company's capital reserve and will not significantly impact the company's operations, finances, or future development [4]